Quviviq(daridorexant)
Quviviq (daridorexant) is a small molecule pharmaceutical. Daridorexant was first approved as Quviviq on 2022-04-07. It has been approved in Europe to treat sleep initiation and maintenance disorders. It is known to target orexin/Hypocretin receptor type 1.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Quviviq
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Daridorexant hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| QUVIVIQ | Idorsia Pharmaceuticals | N-214985 RX | 2022-04-07 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| quviviq | New Drug Application | 2022-03-23 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
DARIDOREXANT HYDROCHLORIDE, QUVIVIQ, IDORSIA | |||
| 2027-04-07 | NCE | ||
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
31 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 17 | — | — | — | — | 17 | ||
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | 2 | — | — | — | — | 2 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DARIDOREXANT |
| INN | daridorexant |
| Description | Daridorexant, sold under the brand name Quviviq, is an orexin antagonist medication which is used for the treatment of insomnia. Daridorexant is taken by mouth.
|
| Classification | Small molecule |
| Drug class | Orexin receptor antagonist; Hypnotic; Sedative |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1 |
Identifiers
| PDB | — |
| CAS-ID | 1505484-82-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297590 |
| ChEBI ID | — |
| PubChem CID | 91801202 |
| DrugBank | DB15031 |
| UNII ID | LMQ24G57E9 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
HCRTR1
HCRTR1
Organism
Homo sapiens
Gene name
HCRTR1
Gene synonyms
NCBI Gene ID
Protein name
orexin/Hypocretin receptor type 1
Protein synonyms
hypocretin (orexin) receptor 1, Hypocretin receptor type 1, orexin receptor 1, Orexin receptor type 1, Ox-1-R, Ox1-R, Ox1R
Uniprot ID
Mouse ortholog
Hcrtr1 (230777)
orexin/Hypocretin receptor type 1 (Q80T45)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 84 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more